Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 3aflibercept 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Fentanyl 2Cisplatin 2Carboplatin 2tinostamustine 1sodium thiosulfate 1rucaparib 1pelcitoclax 1motexafin lutetium 1entinostat 1cobimetinib 1X-Rays 1Topotecan 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Serotonin Plasma Membrane Transport Proteins 1Ropivacaine 1Radiotherapy 1Radiation 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1Patient Reported Outcome Measures 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × tinostamustine × Sarcoma × Clear all
NCT03345485 2024-10-21

EDO-S101

Mundipharma Research Limited

Phase 1/2 Completed
71 enrolled 39 charts
BreastGastrointestinalGynecologicSarcomaThoracic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Sarcoma, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡